Skip to content
Juxtapid, Lojuxta(lomitapide)
Juxtapid, Lojuxta (lomitapide) is a small molecule pharmaceutical. Lomitapide was first approved as Juxtapid on 2012-12-21. It is used to treat hypercholesterolemia in the USA. It has been approved in Europe to treat hypercholesterolemia.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nutritional and metabolic diseasesD009750
Trade Name
FDA
EMA
Juxtapid
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Lomitapide mesylate
Tradename
Company
Number
Date
Products
JUXTAPIDAmryt PharmaN-203858 RX2012-12-21
4 products, RLD
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
juxtapidNew Drug Application2020-09-28
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hypercholesterolemiaHP_0003124D006937—
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Lomitapide Mesylate, Juxtapid, Amryt
79322682027-08-19U-1316
86181352025-03-07U-1316
92657582025-03-07U-1316
93644702025-03-07U-1851
94336172025-03-07U-1316
98616222025-03-07U-1316
100164042025-03-07U-1316
105559382025-03-07U-1316
ATC Codes
C: Cardiovascular system drugs
— C10: Lipid modifying agents
— C10A: Lipid modifying agents, plain
— C10AX: Other lipid modifying agents in atc
— C10AX12: Lomitapide
HCPCS
No data
Clinical
Clinical Trials
18 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hyperlipoproteinemia type iiD006938EFO_0004911E78.00—14—27
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypercholesterolemiaD006937HP_0003124—3———3
HyperlipidemiasD006949EFO_0003774E78.5—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—3————3
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PregnancyD011247EFO_0002950Z33.1————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameLOMITAPIDE
INNlomitapide
Description
Lomitapide is a member of the class of benzamides obtained by formal condensation of the carboxy group of 4'-(trifluoromethyl)biphenyl-2-carboxylic acid with the primary amino group of 9-[4-(4-aminopiperidin-1-yl)butyl]-N-(2,2,2-trifluoroethyl)-9H-fluorene-9-carboxamide. Used (as its mesylate salt) as a complement to a low-fat diet and other lipid-lowering treatments in patients with homozygous familial hypercholesterolemia. It has a role as an anticholesteremic drug and a MTP inhibitor. It is a member of piperidines, a member of fluorenes, a member of benzamides and a member of (trifluoromethyl)benzenes. It is a conjugate base of a lomitapide(1+).
Classification
Small molecule
Drug classmicrosomal triglyceride transfer protein (MTP) inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
O=C(NC1CCN(CCCCC2(C(=O)NCC(F)(F)F)c3ccccc3-c3ccccc32)CC1)c1ccccc1-c1ccc(C(F)(F)F)cc1
Identifiers
PDB—
CAS-ID182431-12-5
RxCUI1364479
ChEMBL IDCHEMBL354541
ChEBI ID72297
PubChem CID9853053
DrugBankDB08827
UNII ID82KUB0583F (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Lomitapide - Amryt Pharma
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Lomitapide - NOVELION THERAPEUTICS INC.
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 652 documents
View more details
Safety
Black-box Warning
Black-box warning for: Juxtapid
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
9,568 adverse events reported
View more details